Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20449099 | 1.00 | PARP1 (0.53) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL2706487 | 0.92 | PARP1 (0.48) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL20449106 | 0.92 | PARP1 (0.48) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL3056493 | 0.92 | TMEM97 (0.50) | PARP1TMEM97SIGMAR1MEN1KMT2A | |
| SCHEMBL20703649 | 0.89 | SIGMAR1 (0.50) | PARP1TMEM97SIGMAR1 | |
| SCHEMBL30711232 | 0.89 | L3MBTL1 (0.47) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL17788032 | 0.89 | L3MBTL1 (0.47) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL3066321 | 0.89 | SIGMAR1 (0.50) | PARP1TMEM97SIGMAR1 | |
| SCHEMBL3068759 | 0.88 | PARP1 (0.48) | PARP1TMEM97SIGMAR1PSEN1PSEN2 | |
| SCHEMBL21625231 | 0.88 | TMEM97 (0.47) | PARP1TMEM97SIGMAR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-10-30 | — | — | US | disclosed |
| EP-4551556-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119546575-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024010784-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4051386-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114650868-A | Small molecule degradation agent of HELIOS and use method thereof | 达纳-法伯癌症研究公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-108290881-B | Therapeutic compounds and methods of use thereof | 健泰科生物技术公司 | 2021-12-07 | — | — | CN | disclosed |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-10 | — | — | US | disclosed |
| EP-2231558-A1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-04-15 | — | — | US | disclosed |
| EP-1513814-B1 | NOVEL PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| WO-2009078932-A1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009078932-A1 | 3,4-SUBSTITUTED PYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| EP-1513814-A4 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20050239829-A1 | Novel piperidine compound | TANABE SEIYAKU CO. LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1513814-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099787-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | IKZF2, IKZF1, HELZ | PARP1 3104/4885TMEM97 3084/4885SIGMAR1 3697/4885 |
| US-20250332156-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | RECQL, BLM, WRN | PARP1 150/4885TMEM97 3777/4885SIGMAR1 4459/4885 |
| US-20050239829-A1 | Novel piperidine compound | EP300, BRD1, CBR3 | PARP1 925/4885TMEM97 654/4885SIGMAR1 14/4885 |
| US-20100093665-A1 | SILYLATED PIPERIDINE DERIVATIVES | PSEN1, PSEN2, SRM | PARP1 244/4885TMEM97 273/4885SIGMAR1 20/4885 |
| US-20210171516-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | AVPR1B, C3AR1, RHEB | PARP1 1568/4885TMEM97 3436/4885SIGMAR1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.